

ELEVEN BIOTHERAPEUTICS, INC.

FORM DEFA14A

(Additional Proxy Soliciting Materials (definitive))

Filed 04/07/17

Address	245 FIRST STREET SUITE 1800 CAMBRIDGE, MA 02142
Telephone	617-444-8550
CIK	0001485003
Symbol	EBIO
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 14A
(Rule 14a-101)**

**Information Required in Proxy Statement
Schedule 14A Information**

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Eleven Biotherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:

 - (2) Aggregate number of securities to which transaction applies:

 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 - (4) Proposed maximum aggregate value of transaction:

 - (5) Total fee paid:

- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:

 - (2) Form, Schedule or Registration Statement No.:

 - (3) Filing Party:

 - (4) Date Filed:



Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on May 19, 2017 for Eleven Biotherapeutics, Inc.

This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement, annual report, directions to the annual meeting and voting instructions, go to www.proxydocs.com/ebio. To submit your proxy while visiting this site, you will need the 12 digit control number in the box below.



Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our 2017 Annual Meeting and need YOUR participation.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's Annual Meeting, please make this request on or before May 9, 2017.



For a Convenient Way to VIEW Proxy Materials – and – VOTE Online go to: www.proxydocs.com/ebio

Proxy Materials Available to View or Receive:
Annual Report and Proxy Statement

Printed materials may be requested by one of the following methods:


INTERNET
www.investorelections.com/ebio


TELEPHONE
(866) 648-8133


*E-MAIL
paper@investorelections.com

You must use the 12 digit control number located in the shaded gray box below.



Eleven Biotherapeutics, Inc. Notice of Annual Meeting



Meeting Type: Annual Meeting
 For holders as of: March 27, 2017
 Date: Friday, May 19, 2017
 Time: 10:00 A.M. (Eastern Time)
 Place: Hilton Boston Logan Airport
 One Hotel Drive
 Boston, MA 02128

The Board of Directors Recommends a Vote FOR each of the director nominees listed in proposal 1 and FOR proposal 2.

1. To elect three class III directors of our board of directors, each to serve until the 2020 annual meeting of stockholders and until their respective successors have been duly elected and qualified.

Nominees: (01) Abbie Celniker
 (02) Jane Henderson
 (03) Daniel Lynch

2. To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2017.
Note: To consider and act upon such other business as may properly come before the meeting or any adjournment thereof.

Vote In-Person Instructions: While we encourage stockholders to vote by the means indicated above, a stockholder is entitled to vote in person at the Annual Meeting. If you wish to vote your shares at the Annual Meeting, please register with the Inspector of Elections at the desk marked "Stockholder Registration" at the entrance to receive a ballot. Proper photo ID is required. Ballots should be returned to the Inspector of Elections in order to be counted. Additionally, a stockholder who has submitted a proxy before the meeting, may revoke that proxy in person at the Annual Meeting.